Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Stephen Strickland
Phase I Trial of Isatuximab Monotherapy in the Treatment of Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 With Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE ‐013
British Journal of Haematology
Hematology
Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Trial of Flavopiridol in Relapsed Multiple Myeloma
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design
Future Oncology
Medicine
Cancer Research
Oncology
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
Cancer Science
Cancer Research
Medicine
Oncology
Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib
Blood Cancer Journal
Oncology
Hematology
Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
